Blood test using DNA methylation to tell kidney cancer from benign kidney masses
Studies a blood test to classify kidney masses before surgery in adults.
Plain-language title generated from the registry record
Registry title: Plasma DNA Methylation for Preoperative Classification of Renal Masses
Key facts
- Where
- Shanghai, ChinaSee the site
Where in China
- RenJi HospitalShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- RenJi Hospital
- Trial code
- NCT07874542
- Record updated
- 15 October 2026
- Original description
METH-RENAL is a prospective observational diagnostic development and threshold-setting study in adults with a renal mass scheduled for partial or radical nephrectomy. Peripheral blood is collected before surgery, and postoperative histopathology serves as the reference standard. The study will develop and internally validate a plasma DNA methylation classifier and lock the final marker panel, algorithm, and positivity cut-off for a subsequent independent prospective multicenter validation study.Read full original descriptionShow less
METH-RENAL: A Prospective Clinical Development and Threshold-Setting Study of a Plasma DNA Methylation Classifier for the Preoperative Evaluation of Renal Masses
METH-RENAL is a prospective observational diagnostic development and threshold-setting study in adults with a renal mass scheduled for partial or radical nephrectomy. Peripheral blood is collected before surgery, and postoperative histopathology serves as the reference standard. The study will develop and internally validate a plasma DNA methylation classifier and lock the final marker panel, algorithm, and positivity cut-off for a subsequent independent prospective multicenter validation study.
Inclusion: 3.Partial nephrectomy or radical nephrectomy planned as part of routine clinical care; 4.Preoperative peripheral blood collection feasible before surgery or other treatment of the index lesion; 5.Final postoperative histopathological diagnosis expected to be available. 6.Written informed consent provided; -.
Exclusion: 8.Concurrent active malignancy requiring systemic treatment that, in the investigator's judgment, could materially interfere with interpretation of the methylation assay; 9.Severe acute infection or another uncontrolled systemic condition that could compromise biospecimen quality or study procedures; 10.Inadequate preoperative blood specimen or failure of prespecified analytical quality-control requirements; 11.No definitive pathological diagnosis of the index renal lesion. Any condition that, in the investigator's judgment, makes participation inappropriate; -.